A startup company has taken aim at drug counterfeiting in developing countries with a technology that relies on cell phones and what it refers to on its website as "crowd-sourced pharmacovigilance."
The reasons behind the dealmaking aren't new: Established markets are slowing down as emerging markets speed up, sending companies shopping in the developing world.
Melbourne researchers with the Monash Vision Group, who are on track to have a direct-to-brain bionic eye implant ready for human trials next year, are ready to test its first full system prototype this month.
Earnings season continues, and this morning, Covidien ($COV) released positive results in a quarter that witnessed a 7% rise in device sales.
Watson Pharmaceuticals has agreed to buy its Swiss-based rival Actavis. The price was about what the gossips expected: a total of $5.9 billion.
Sandoz sees lots of potential but is taking an indirect route to build a production footprint in sub-Saharan Africa.
Expect Johnson & Johnson ($JNJ) to start spending some of its $14 billion in cash on medical device deals to help expand its presence in emerging markets once Alex Gorsky becomes CEO.
Chiltern, an international contract research organization, landed a legal entity in Taiwan, enabling it to conduct clinical trial services in the island nation.
Sales growth surpassing 21% in the Asia-Pacific region helped produce healthy numbers for French in vitro diagnostics player bioMérieux in the company's 2012 first quarter.
Last week, we profiled EnteroMedics' ($ETRM) seeming rise from the ashes. Today, it's reporting its first product revenues.